Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

10.1093/ofid/ofab387

Saved in:

Bibliographic Details
Main Authors:	Stewart, AG, Paterson, DL, Young, B, Lye, DC, Davis, JS, Schneider, K, Yilmaz, M, Dinleyici, R, Runnegar, N, Henderson, A, Archuleta, S, Kalimuddin, S, Forde, BM, Chatfield, MD, Bauer, MJ, Lipman, J, Harris-Brown, T, Harris, PNA
Other Authors:	MEDICINE
Format:	Article
Published:	Oxford University Press (OUP) 2021
Subjects:	Enterobacterales ampC β-lactamase carbapenem clinical trial piperacillin-tazobactam
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/206194
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.1093/ofid/ofab387